Edition:
United States

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

4.06USD
22 Jun 2018
Change (% chg)

$-0.07 (-1.69%)
Prev Close
$4.13
Open
$4.14
Day's High
$4.14
Day's Low
$4.03
Volume
33,453
Avg. Vol
57,335
52-wk High
$4.55
52-wk Low
$1.07

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $125.80
Shares Outstanding(Mil.): 31.07
Dividend: --
Yield (%): --

Financials

  APTO.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -0.57 -- --
ROI: -136.61 -5.25 13.10
ROE: -136.61 -6.83 15.09

BRIEF-Aptose Reports Q1 Loss Per Share $0.23

* APTOSE REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018

May 10 2018

BRIEF-Aptose Biosciences Says Exercises Early Option For Cg-806 License From Crystalgenomics

* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS

May 07 2018

BRIEF-Aptose Biosciences Establishes New At-The-Market Facility

* APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO

Mar 28 2018

BRIEF-Aptose Reports Qtrly Loss Of $0.12‍​ Per Share

* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

Mar 27 2018

BRIEF-Aptose Biosciences Announces License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology ‍​

* APTOSE BIOSCIENCES - ‍ AGREEMENT PROVIDES OHM ONCOLOGY RIGHTS FOR DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION OF APL-581

Mar 07 2018

BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln

* APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text : http://bit.ly/2BJGvqH Further company coverage:

Feb 07 2018

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

Dec 26 2017

Earnings vs. Estimates